Cargando…
Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated. Challenges facing current drugs that are part of the established life-long antiretroviral therapy (ART) include toxicity, development of dru...
Autores principales: | Mohamed, Hager, Gurrola, Theodore, Berman, Rachel, Collins, Mackenzie, Sariyer, Ilker K., Nonnemacher, Michael R., Wigdahl, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811197/ https://www.ncbi.nlm.nih.gov/pubmed/35126374 http://dx.doi.org/10.3389/fimmu.2021.816515 |
Ejemplares similares
-
Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy
por: Atkins, Andrew, et al.
Publicado: (2021) -
Immunomodulatory Effects of Non-Thermal Plasma in a Model for Latent HIV-1 Infection: Implications for an HIV-1-Specific Immunotherapy
por: Mohamed, Hager, et al.
Publicado: (2023) -
The Expanding Therapeutic Perspective of CCR5 Blockade
por: Vangelista, Luca, et al.
Publicado: (2018) -
Extracellular HIV-1 Tat Mediates Increased Glutamate in the CNS Leading to Onset of Senescence and Progression of HAND
por: Marino, Jamie, et al.
Publicado: (2020) -
Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in HIV-1 Disease
por: Maubert, Monique E., et al.
Publicado: (2017)